137.33
137.33 (0%)
As of Feb 14, 2025
BIOGEN INC. [BIIB]
Source:
Company Overview
Biogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases worldwide. We have a broad portfolio of medicines to treat multiple sclerosis (MS), have introduced the first approved treatment for spinal muscular atrophy (SMA) and co-developed two treatments to address a defining pathology of Alzheimer’s disease.
| Country | United States |
| Headquarters | cambridge, massachusetts |
| Phone Number | (617) 679-2000 |
| Industry | manufacturing |
| CEO | Christopher A. Viehbacher |
| Website | www.biogen.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $2,465.8 |
| Operating Profit | |
| Net Income | $388.5 |
| Net Cash | $642.6 |
Profit Ratios
| Gross Margin | $1,827.1 |
| Operating Margin | |
| Profit as % of Revenues | 470.3% |
| Profit as % of Assets | 2.5% |
| Profit as % of Stockholder Equity | 2.4% |
Management Effectiveness
| Return on Equity | 2.4% |
| Return on Assets | 1.4% |
| Turnover Ratio | 16% |
| EBITA | $130.3 |
Balance Sheet and Cash Flow Measures
| Total Assets | $28,313.2 |
| Total Liabilities | $11,954.3 |
| Operating Cash Flow | $2,114.6 |
| Investing Cash Flow | $-780.6 |
| Financing Cash Flow | $-691.4 |
